Enzon Shareholders Approve Reverse Split and Viskase Merger

Enzon Pharmaceuticals ( (ENZN) ) has provided an update.

On February 11, 2026, Enzon Pharmaceuticals, Inc. reported that its stockholders had approved a 1-for-100 reverse stock split of its common shares through a written consent process. The reverse split amendment to the company’s charter was backed by holders of about 55.2% of the outstanding stock as of the January 29, 2026 record date, with 40,993,338 shares voting in favor.

On the same date, shareholders also approved the adoption of Enzon’s merger agreement with Viskase Companies, Inc. and EPSC Acquisition Corp., with support from 57.1% of the outstanding shares, or 42,350,448 shares. The consent solicitation and revocation period ended at 8:00 a.m. Eastern Time on February 11, 2026, and closing of the merger remains contingent on satisfaction or waiver of remaining conditions under the merger agreement, leaving investors focused on execution risks and timing to completion.

More about Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company whose common stock is quoted on the over-the-counter markets. The company has in recent years focused largely on managing its existing assets and pursuing strategic transactions rather than actively developing a broad pipeline of new therapeutics.

Average Trading Volume: 84,570

Technical Sentiment Signal: Sell

Current Market Cap: $5.01M

Learn more about ENZN stock on TipRanks’ Stock Analysis page.